gliptin and glp-1 Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus The Role of DPP-4 Inhibitors

This is due to the reduced incidence of prediabetes in patients with obesity [37, 46, 47] and improved markers for ovarian function in patients with obesity and PCOS [66], compared with placebo

Around the same time, companies like Novo Nordisk began medicinal chemistry efforts to create modified human GLP-1 analogues with longer half-lives (for example, by adding fatty acid chains to help the peptide bind to albumin and resist degradation) ( [47] ) ( [48] )

The short answer: No

Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia), and stomach (abdominal) pain have been reported

Tirzepatide often produces greater average weight loss

Gray-market vials from overseas pharmacies